MaaT Pharma Announces New Appointments to the Board and Executive Team

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to improving survival outcomes for patients with cancer, today announced new appointments to its Board and Executive team.

Board of Directors

• Karim Dabbagh, PhD, is appointed as Chairman and independent Director, succeeding Jean-Marie Lefèvre who will continue to serve as a Board member. Based in the U.S., Karim Dabbagh, president and CEO of Second Genome Inc., is renowned for his innovative work in microbiome science. As former executive at Pfizer and Roche, he brings extensive experience in pharmaceutical development.
• Nadia Kamal, PhD, Director of the Technology, Health, and Innovation Divisions at Harmonie Mutuelle has been appointed as independent director and Chair of the ESG committee. Nadia Kamal has a wealth of experience in Corporate Social Responsibility and a strong background in serving patients and fostering innovation.
• All other Directors and Observers have been reelected to serve for an additional one-year term. Further details can be found on the Company’s website.

“I express gratitude to Jean-Marie Lefèvre for his remarkable 5-year tenure as Chairman, who was instrumental in achieving key milestones and has been a true partner for me. As we embark on the next phase of growth post-IPO, our governance evolves, therefore, I warmly welcome Karim Dabbagh to the team and am eager to continue building a successful microbiome company together,” said Hervé Affagard, CEO and co-founder of MaaT Pharma. "Our expanding Early Access program and ongoing trials address the growing interest from the medical community and patients. The potential for microbiome therapies as valid therapeutic options for patients is demonstrated by the successful commercialization of recently approved products in the U.S. for C. difficile infection and the 2023 ASCO spotlight.”

Jean-Marie Lefèvre, former chairman of MaaT Pharma, said “It has been an honor to serve alongside Hervé and his dedicated and passionate team. As I pass the baton to Karim Dabbagh, I carry with me a deep sense of fulfillment for what we have accomplished and look forward to continuing to serve on the Board. “

Karim Dabbagh, new Chairman of the Board, stated “I am thrilled to join one of the companies at the forefront of the global microbiome field. The groundbreaking advancements and pioneering research undertaken by MaaT Pharma have truly set them apart. I look forward to contributing to their continued success as we strive to make a lasting impact on the future of microbiome innovation for patients, while delivering value to our shareholders.”